A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer
A pilot study was undertaken in eight patients to assess the feasibility of recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1994-03, Vol.69 (3), p.537-540 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 540 |
|---|---|
| container_issue | 3 |
| container_start_page | 537 |
| container_title | British journal of cancer |
| container_volume | 69 |
| creator | KEHOE, S POOLE, C. J STANLEY, A EARL, H. M BLACKLEDGE, G. R. P |
| description | A pilot study was undertaken in eight patients to assess the feasibility of recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed the course of six cycles of cisplatin 75 mg m-2 and cyclophosphamide 750 mg m-2 with rH GM-CSF, 3-5 micrograms kg-1 day-1, days 3-14, but one of these suffered a toxic death on study. Another died of disease progression. There were two episodes of life-threatening infection (WHO grade 4), and three patients were withdrawn because of various rH GM-CSF-related problems. Although potentially affording some patients the hypothetical benefits of dose intensification, as well as the possible attraction of a shorter duration of chemotherapy, this regimen is not without problems. |
| doi_str_mv | 10.1038/bjc.1994.97 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1968837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16814552</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-a7b8887c5a4f28f0068ff18d26ba107e11c35098a0e19ab719a70270dcbf04d3</originalsourceid><addsrcrecordid>eNpVkU1r3DAQhk1pSTdpTz2X6lByKd5I_pJ8CYTQj4VAL7mLsSytFWxpK8kL_mv9dR13l6W9aBDvO88M82bZB0a3jJbirntRW9a21bblr7INq8siZ6Lgr7MNpZTntC3o2-w6xhf8tlTwq-xKsKKsRLXJfj-QwwBRk93dbkdSsDASb0jQyk-ddeASGeYJHNkHcPPo1ZJ0PoEKHtv2mig_erfkMdlpHiFZtycGVPKBWEfSoLEk7aI1VqHq3QpXNh7-egm4nqhFjQjzEYGT7RE56Mlja4DDQgySoD-CU7on_gi4oCNq_YZ32RsDY9Tvz_Ume_729fnxR_708_vu8eEpV1VDUw68E0JwVUNlCmEobYQxTPRF0wGjXDOmypq2AqhmLXQcH04LTnvVGVr15U12f8Ie5m7SvdIuBRjlIdgJwiI9WPm_4uwg9_4oWdsIUXIE3J4Bwf-adUxyslHpcQSn_RwlawSr6rpA45eTEa8bY9DmMoRRuSYtMWm5Ji3bFfvx370u3nO0qH8-6xAVjAbzw8NfbGXLRUUbtH062RykOeiLjqPWSTjoD-dZwmQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16814552</pqid></control><display><type>article</type><title>A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>KEHOE, S ; POOLE, C. J ; STANLEY, A ; EARL, H. M ; BLACKLEDGE, G. R. P</creator><creatorcontrib>KEHOE, S ; POOLE, C. J ; STANLEY, A ; EARL, H. M ; BLACKLEDGE, G. R. P</creatorcontrib><description>A pilot study was undertaken in eight patients to assess the feasibility of recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed the course of six cycles of cisplatin 75 mg m-2 and cyclophosphamide 750 mg m-2 with rH GM-CSF, 3-5 micrograms kg-1 day-1, days 3-14, but one of these suffered a toxic death on study. Another died of disease progression. There were two episodes of life-threatening infection (WHO grade 4), and three patients were withdrawn because of various rH GM-CSF-related problems. Although potentially affording some patients the hypothetical benefits of dose intensification, as well as the possible attraction of a shorter duration of chemotherapy, this regimen is not without problems.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1994.97</identifier><identifier>PMID: 8123484</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma, Mucinous - drug therapy ; Adenocarcinoma, Mucinous - mortality ; Adenocarcinoma, Mucinous - pathology ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Feasibility Studies ; Female ; Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use ; Granulocyte-Macrophage Colony-Stimulating Factor - toxicity ; Humans ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Pharmacology. Drug treatments ; Recombinant Proteins - therapeutic use ; Recombinant Proteins - toxicity ; Survival Rate</subject><ispartof>British journal of cancer, 1994-03, Vol.69 (3), p.537-540</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-a7b8887c5a4f28f0068ff18d26ba107e11c35098a0e19ab719a70270dcbf04d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968837/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968837/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3978406$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8123484$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KEHOE, S</creatorcontrib><creatorcontrib>POOLE, C. J</creatorcontrib><creatorcontrib>STANLEY, A</creatorcontrib><creatorcontrib>EARL, H. M</creatorcontrib><creatorcontrib>BLACKLEDGE, G. R. P</creatorcontrib><title>A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>A pilot study was undertaken in eight patients to assess the feasibility of recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed the course of six cycles of cisplatin 75 mg m-2 and cyclophosphamide 750 mg m-2 with rH GM-CSF, 3-5 micrograms kg-1 day-1, days 3-14, but one of these suffered a toxic death on study. Another died of disease progression. There were two episodes of life-threatening infection (WHO grade 4), and three patients were withdrawn because of various rH GM-CSF-related problems. Although potentially affording some patients the hypothetical benefits of dose intensification, as well as the possible attraction of a shorter duration of chemotherapy, this regimen is not without problems.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma, Mucinous - drug therapy</subject><subject>Adenocarcinoma, Mucinous - mortality</subject><subject>Adenocarcinoma, Mucinous - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - toxicity</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Recombinant Proteins - toxicity</subject><subject>Survival Rate</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1r3DAQhk1pSTdpTz2X6lByKd5I_pJ8CYTQj4VAL7mLsSytFWxpK8kL_mv9dR13l6W9aBDvO88M82bZB0a3jJbirntRW9a21bblr7INq8siZ6Lgr7MNpZTntC3o2-w6xhf8tlTwq-xKsKKsRLXJfj-QwwBRk93dbkdSsDASb0jQyk-ddeASGeYJHNkHcPPo1ZJ0PoEKHtv2mig_erfkMdlpHiFZtycGVPKBWEfSoLEk7aI1VqHq3QpXNh7-egm4nqhFjQjzEYGT7RE56Mlja4DDQgySoD-CU7on_gi4oCNq_YZ32RsDY9Tvz_Ume_729fnxR_708_vu8eEpV1VDUw68E0JwVUNlCmEobYQxTPRF0wGjXDOmypq2AqhmLXQcH04LTnvVGVr15U12f8Ie5m7SvdIuBRjlIdgJwiI9WPm_4uwg9_4oWdsIUXIE3J4Bwf-adUxyslHpcQSn_RwlawSr6rpA45eTEa8bY9DmMoRRuSYtMWm5Ji3bFfvx370u3nO0qH8-6xAVjAbzw8NfbGXLRUUbtH062RykOeiLjqPWSTjoD-dZwmQ</recordid><startdate>19940301</startdate><enddate>19940301</enddate><creator>KEHOE, S</creator><creator>POOLE, C. J</creator><creator>STANLEY, A</creator><creator>EARL, H. M</creator><creator>BLACKLEDGE, G. R. P</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>19940301</creationdate><title>A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer</title><author>KEHOE, S ; POOLE, C. J ; STANLEY, A ; EARL, H. M ; BLACKLEDGE, G. R. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-a7b8887c5a4f28f0068ff18d26ba107e11c35098a0e19ab719a70270dcbf04d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma, Mucinous - drug therapy</topic><topic>Adenocarcinoma, Mucinous - mortality</topic><topic>Adenocarcinoma, Mucinous - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - toxicity</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Recombinant Proteins - toxicity</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KEHOE, S</creatorcontrib><creatorcontrib>POOLE, C. J</creatorcontrib><creatorcontrib>STANLEY, A</creatorcontrib><creatorcontrib>EARL, H. M</creatorcontrib><creatorcontrib>BLACKLEDGE, G. R. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KEHOE, S</au><au>POOLE, C. J</au><au>STANLEY, A</au><au>EARL, H. M</au><au>BLACKLEDGE, G. R. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>1994-03-01</date><risdate>1994</risdate><volume>69</volume><issue>3</issue><spage>537</spage><epage>540</epage><pages>537-540</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>A pilot study was undertaken in eight patients to assess the feasibility of recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed the course of six cycles of cisplatin 75 mg m-2 and cyclophosphamide 750 mg m-2 with rH GM-CSF, 3-5 micrograms kg-1 day-1, days 3-14, but one of these suffered a toxic death on study. Another died of disease progression. There were two episodes of life-threatening infection (WHO grade 4), and three patients were withdrawn because of various rH GM-CSF-related problems. Although potentially affording some patients the hypothetical benefits of dose intensification, as well as the possible attraction of a shorter duration of chemotherapy, this regimen is not without problems.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>8123484</pmid><doi>10.1038/bjc.1994.97</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1994-03, Vol.69 (3), p.537-540 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1968837 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma, Mucinous - drug therapy Adenocarcinoma, Mucinous - mortality Adenocarcinoma, Mucinous - pathology Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cisplatin - administration & dosage Cisplatin - adverse effects Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Feasibility Studies Female Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use Granulocyte-Macrophage Colony-Stimulating Factor - toxicity Humans Medical sciences Middle Aged Neoplasm Staging Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Pharmacology. Drug treatments Recombinant Proteins - therapeutic use Recombinant Proteins - toxicity Survival Rate |
| title | A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A40%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20I/II%20trial%20of%20recombinant%20human%20granulocyte-macrophage%20colony-stimulating%20factor%20in%20the%20intensification%20of%20cisplatin%20and%20cyclophosphamide%20chemotherapy%20for%20advanced%20ovarian%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=KEHOE,%20S&rft.date=1994-03-01&rft.volume=69&rft.issue=3&rft.spage=537&rft.epage=540&rft.pages=537-540&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1994.97&rft_dat=%3Cproquest_pubme%3E16814552%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16814552&rft_id=info:pmid/8123484&rfr_iscdi=true |